Table 1.
Patient characteristics before and after PSM in the CRT and CT alone groups.
| Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|
| Factor | Level | CT (n = 93) | CRT (n = 101) | p | CT (n = 63) | CRT (n = 63) | p |
| Gender | Male | 86 | 91 | 0.741 | 58 | 57 | 1.000 |
| Female | 7 | 10 | 5 | 6 | |||
| Age (yrs, mean ± SD) | 57.4 ( ± 0.9) | 56.1 ( ± 0.9) | 0.298 | 56.3 ( ± 1.0) | 55.0 ( ± 1.1) | 0.149 | |
| BMI (m2/kg, mean ± SD) | 20.3 ( ± 0.3) | 21.5 ( ± 0.3) | 0.010 | 20.8 ( ± 0.4) | 21.0 ( ± 0.3) | 0.687 | |
| ECOG | 0 | 8 | 10 | 0.011 | 5 | 3 | 0.715 |
| 1 | 77 | 91 | 58 | 60 | |||
| 2 | 8 | 0 | |||||
| Smoking | No | 25 | 38 | 0.149 | 17 | 23 | 0.339 |
| Yes | 68 | 63 | 46 | 40 | |||
| Drinking | No | 25 | 32 | 0.565 | 17 | 22 | 0.441 |
| Yes | 68 | 69 | 46 | 41 | |||
| Family history | No | 89 | 92 | 0.320 | 61 | 59 | 0.676 |
| Yes | 4 | 9 | 2 | 4 | |||
| T stage | 2 | 6 | 4 | 1.146 | 3 | 1 | 0.457 |
| 3 | 26 | 18 | 17 | 14 | |||
| 4 | 61 | 79 | 43 | 48 | |||
| N stage | 1 | 31 | 36 | 1.140 | 21 | 24 | 0.310 |
| 2 | 40 | 52 | 30 | 33 | |||
| 3 | 22 | 13 | 12 | 6 | |||
| Number of metastatic sites | 0 | 32 | 65 | 0.001 | 30 | 35 | 0.669 |
| 1 | 48 | 29 | 28 | 24 | |||
| 2 | 7 | 7 | 5 | 4 | |||
| ≥3 | 6 | 0 | 0 | 0 | |||
| TNM stage | IVa | 32 | 65 | 0.000 | 30 | 35 | 1.000 |
| IVb | 61 | 36 | 33 | 28 | |||
| Tumor location | Up | 20 | 29 | 0.114 | 11 | 16 | 0.271 |
| Middle | 46 | 57 | 34 | 36 | |||
| Down | 27 | 14 | 16 | 11 | |||
| Multiple lesions | 2 | 1 | 2 | 0 | |||
| HBG (g/L, mean ± SD) | 123.1 ( ± 1.6) | 123.3 ( ± 1.8) | 0.920 | 122.1 ( ± 1.9) | 124.3 ( ± 2.2) | 0.450 | |
| PLT (109/L, mean ± SD) | 318.9 ( ± 11.1) | 302.8 ( ± 8.3) | 0.248 | 300.2 ( ± 12.4) | 318.8 ( ± 12.2) | 0.288 | |
| NEU (109/L, mean ± SD) | 5.9 ( ± 0.3) | 5.1 ( ± 0.2) | 0.022 | 5.4 ( ± 0.3) | 5.2 ( ± 0.3) | 0.691 | |
| LYMPH (109/L, mean ± SD) | 1.9 ( ± 0.1) | 2.0 ( ± 0.2) | 0.573 | 2.0 ( ± 0.2) | 1.8 ( ± 0.1) | 0.338 | |
| ALB (g/L, mean ± SD) | 35.5 ( ± 0.5) | 36.7 ( ± 0.4) | 0.047 | 36.8 ( ± 0.6) | 37.7 ( ± 0.6) | 0.248 | |
| AST (U/L, mean ± SD) | 17.1 ( ± 1.1) | 17.2 ( ± 1.0) | 0.973 | 18.1 ( ± 1.7) | 17.2 ( ± 1.4) | 0.670 | |
| ALT (U/L, mean ± SD) | 25.2 ( ± 1.6) | 22.7 ( ± 0.8) | 0.159 | 26.4 ( ± 2.4) | 22.3 ( ± 1.0) | 0.118 | |
| Urea (mmol/L, mean ± SD) | 4.8 ( ± 0.2) | 4.7 ( ± 0.0) | 0.786 | 4.7 ( ± 0.2) | 4.5 ( ± 0.2) | 0.517 | |
| Creatinine (μmol/L, mean ± SD) | 78.3 ( ± 2.5) | 76.9 ( ± 1.4) | 0.630 | 78.1 ( ± 3.1) | 76.1 ( ± 1.8) | 0.589 | |
| Chemotherapy cycle | ≤3 | 62 | 57 | 0.144 | 43 | 35 | 0.142 |
| >3 | 31 | 44 | 20 | 28 | |||
BMI, body mass index; ECOG score, Eastern Cooperative Oncology Group; WBC, white blood cell counts; HGB, hemoglobin level; PLT, blood platelet count; NEU, absolute neutrophil count; LYMPH, absolute lymphocyte count; ALB, albumin level; ALT, alanine aminotransferase level; AST, aspartate aminotransferase level.